NEWARK, Calif., Sept. 1, 2016 /PRNewswire/ -- DNA2.0 Inc., a pioneer in bioengineering solutions, today announced the issuance of a patent by the U.S. Patent and Trademark Office (USPTO) for LeapIn, the company's innovative transposon- and transposase-based tool. Patent No. 9,428,767 entitled "Enhanced nucleic acid constructs for eukaryotic gene expression," covers configurations of vectors for improved heterologous gene expression, methods for identifying these configurations and the use of transposons and transposases."Our transposon-, and transposase-based tools have applications in gene expression, gene therapy and gene discovery," saidKate Caves, director of business development and marketing at DNA2.0 and a biologist who was one of the inventors. "We have already seen strong interest from protein pharmaceutical companies in our proprietary tools for transient and stable protein production in mammalian hosts. Now more than ever, we are in a position to apply our bioengineering tools to the entire spectrum of scale, from building better genes, proteins and pathways all the way to genomes."
NEWARK, Calif., Sept. 1, 2016 /PRNewswire/ -- DNA2.0 Inc., a pioneer in bioengineering solutions, today announced the issuance of a patent by the U.S. Patent and Trademark Office (USPTO) for LeapIn, the company's innovative transposon- and transposase-based tool. Patent No. 9,428,767 entitled "Enhanced nucleic acid constructs for eukaryotic gene expression," covers configurations of vectors for improved heterologous gene expression, methods for identifying these configurations and the use of transposons and transposases."Our transposon-, and transposase-based tools have applications in gene expression, gene therapy and gene discovery," saidKate Caves, director of business development and marketing at DNA2.0 and a biologist who was one of the inventors. "We have already seen strong interest from protein pharmaceutical companies in our proprietary tools for transient and stable protein production in mammalian hosts. Now more than ever, we are in a position to apply our bioengineering tools to the entire spectrum of scale, from building better genes, proteins and pathways all the way to genomes."